Research programme: allergy vaccines - Anergis

Drug Profile

Research programme: allergy vaccines - Anergis

Alternative Names: AllerDM; AllerDM dust mites - Anergis; AllerG; AllerG grass - Anergis; AllerJ; AllerJ Japanese cedar - Anergis; AllerR; AllerR ragweed - Anergis

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Lausanne
  • Developer Anergis
  • Class Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity
  • No development reported Bee venom hypersensitivity; Grass pollen hypersensitivity; Ragweed pollen hypersensitivity; Tree pollen hypersensitivity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bee-venom-hypersensitivity(Prevention) in Switzerland (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ragweed pollen hypersensitivity(Prevention) in Switzerland (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for research development in Grass pollen hypersensitivity(Prevention) in Switzerland (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top